FY2025 EPS Estimate for Larimar Therapeutics Cut by Analyst

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Stock analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of Larimar Therapeutics in a research note issued on Tuesday, March 25th. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of ($1.91) for the year, down from their prior forecast of ($1.77). HC Wainwright currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ FY2026 earnings at ($2.10) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.16).

LRMR has been the subject of several other reports. Guggenheim reissued a “buy” rating and issued a $26.00 price objective on shares of Larimar Therapeutics in a research note on Tuesday. Truist Financial initiated coverage on shares of Larimar Therapeutics in a research report on Wednesday, January 29th. They set a “buy” rating and a $18.00 target price for the company. Finally, Robert W. Baird reduced their target price on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating for the company in a research note on Tuesday. Eleven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Larimar Therapeutics currently has an average rating of “Buy” and a consensus price target of $20.22.

Larimar Therapeutics Stock Performance

Shares of NASDAQ LRMR opened at $2.35 on Thursday. The stock has a market cap of $149.95 million, a price-to-earnings ratio of -2.04 and a beta of 0.99. Larimar Therapeutics has a fifty-two week low of $2.19 and a fifty-two week high of $11.20. The firm’s 50-day simple moving average is $3.08 and its 200 day simple moving average is $5.12.

Hedge Funds Weigh In On Larimar Therapeutics

Institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC boosted its position in shares of Larimar Therapeutics by 27.2% in the 3rd quarter. Janus Henderson Group PLC now owns 5,566,855 shares of the company’s stock worth $36,379,000 after purchasing an additional 1,189,467 shares in the last quarter. Blue Owl Capital Holdings LP grew its stake in shares of Larimar Therapeutics by 11.7% in the fourth quarter. Blue Owl Capital Holdings LP now owns 4,653,040 shares of the company’s stock worth $18,007,000 after acquiring an additional 486,211 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in Larimar Therapeutics by 23.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock valued at $8,127,000 after buying an additional 399,123 shares during the last quarter. Alyeska Investment Group L.P. increased its position in Larimar Therapeutics by 38.6% during the fourth quarter. Alyeska Investment Group L.P. now owns 984,077 shares of the company’s stock valued at $3,808,000 after acquiring an additional 273,920 shares during the last quarter. Finally, Cubist Systematic Strategies LLC lifted its stake in shares of Larimar Therapeutics by 278.8% in the 4th quarter. Cubist Systematic Strategies LLC now owns 233,873 shares of the company’s stock worth $905,000 after purchasing an additional 172,131 shares during the period. 91.92% of the stock is owned by institutional investors.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.